Dr. Wucherpfennig will continue to be responsible for coordinating the research efforts among all participating labs at Harvard Medical School, the Massachusetts Institute of Technology and New York University, and for administrative oversight of the entire program. He has worked closely with all investigators involved in this PPG during the current funding period, investigators who are presently funded by this PPG (Hafler and Ploegh) and members who joined the PPG for this renewal (Kuchroo and Turley). The close interactions among the laboratories are facilitated by the close involvement of Drs. Wucherpfennig, Turley, Kuchroo and Hafler in the Immunology Program at Harvard Medical School which the program members serve in many different capacities (i.e. Kuchroo & Wucherpfennig - seminar committee, Hafler &Wucherpfennig - executive committee, Turley & Wucherpfennig - graduate committee). Dr. Ploegh was until recently Director of the Immunology Graduate Program at Harvard Medical School and remains closely involved in the activities of the program. The many informal interactions among the investigators greatly facilitate joint research efforts. Dr. Wucherpfennig will continue to collaborate with all members of this PPG and will identify new opportunities for joint research activities. These will be discussed at joint meetings, which in the past have emphasized the application of new technologies to the investigation of autoimmune diseases in both animal models and patients, as evidenced by the joint development of novel approaches by Drs. Wucherpfennig &Hafler (antigen tetramers) and Drs. Ploegh &Hafler (nanowell technology for investigation of B cell function). Dr. Wucherpfennig will also continue to be in charge of all administrative aspects, and will be assisted by his administrator (Kimberly Foemmel) and Dana-Farber administrators who specialize in grants management (Ms. Jane Macdonald) and financial management (Ms. Linda Shehu). No funding is requested for these Dana-Farber administrators.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-SR-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Lucca, Liliana E; Hafler, David A (2017) Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment. J Clin Invest 127:1218-1220
Nylander, Alyssa N; Ponath, Gerald D; Axisa, Pierre-Paul et al. (2017) Podoplanin is a negative regulator of Th17 inflammation. JCI Insight 2:
Gierahn, Todd M; Wadsworth 2nd, Marc H; Hughes, Travis K et al. (2017) Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput. Nat Methods 14:395-398
Lucca, Liliana E; Hafler, David A (2017) Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immunol Rev 276:9-25
Verbeke, Catia S; Gordo, Susana; Schubert, David A et al. (2017) Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation. Adv Healthc Mater 6:
Singer, Meromit; Wang, Chao; Cong, Le et al. (2016) A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells. Cell 166:1500-1511.e9
Adams, Jarrett J; Narayanan, Samanthi; Birnbaum, Michael E et al. (2016) Structural interplay between germline interactions and adaptive recognition determines the bandwidth of TCR-peptide-MHC cross-reactivity. Nat Immunol 17:87-94
Urso, Katia; Alvarez, David; Cremasco, Viviana et al. (2016) IL4RA on lymphatic endothelial cells promotes T cell egress during sclerodermatous graft versus host disease. JCI Insight 1:
Chastre, Anne; Hafler, David A; O'Connor, Kevin C (2016) Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. N Engl J Med 374:1495-6
Cao, Yonghao; Nylander, Alyssa; Ramanan, Sriram et al. (2016) CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology 86:1553-6

Showing the most recent 10 out of 122 publications